Insider Analysis: The Glivec Patent Saga – Effectuating “Efficacious” Patent Norms In India
This article was originally published in PharmAsia News
Executive Summary
By: Shamnad Basheer
You may also be interested in...
Indian Pharma Lobby Calls For Re-examination Of 81 MNC Drug Patents
MUMBAI - As Indian companies battle multinational drug giants for patent rights, the Indian Pharmaceutical Alliance - an association that represents top Indian drug companies - wrote to the Union Ministry of Commerce and Industry Feb. 14 that a large number of pharmaceutical patents granted over the last four years are granted to new forms of known substances and combinations of old drugs
Indian Pharma Lobby Calls For Re-examination Of 81 MNC Drug Patents
MUMBAI - As Indian companies battle multinational drug giants for patent rights, the Indian Pharmaceutical Alliance - an association that represents top Indian drug companies - wrote to the Union Ministry of Commerce and Industry Feb. 14 that a large number of pharmaceutical patents granted over the last four years are granted to new forms of known substances and combinations of old drugs
As Novartis’ Glivec Hearing Approaches, Indian IP Panel Adds Court-Ordered Technical Member
NEW DELHI - Swiss pharma giant Novartis is "pleased" with the appointment of a new technical member to an Indian panel hearing a high-profile challenge by Novartis regarding the rejection of patent protection for its blockbuster leukemia drug Glivec